TY - JOUR
T1 - Effects of prediabetes on long-term clinical outcomes of patients with acute myocardial infarction who underwent PCI using new-generation drug-eluting stents
AU - Kim, Yong Hoon
AU - Her, Ae Young
AU - Jeong, Myung Ho
AU - Kim, Byeong Keuk
AU - Hong, Sung Jin
AU - Kim, Seunghwan
AU - Ahn, Chul Min
AU - Kim, Jung Sun
AU - Ko, Young Guk
AU - Choi, Donghoon
AU - Hong, Myeong Ki
AU - Jang, Yangsoo
PY - 2020/2
Y1 - 2020/2
N2 - Aims: We investigated the 2-year clinical outcomes of patients with acute myocardial infarction (AMI) and prediabetes after new-generation drug-eluting stents implantation. Methods: A total of 11,962 patients with AMI were classified into normoglycemia (group A; 3,080), prediabetes (group B; 3,709), and diabetes (group C; 5,173) groups. The primary outcomes were the patient-oriented composite outcomes (POCOs) defined as all-cause death, recurrent myocardial infarction (Re-MI), and any repeat revascularization. Secondary outcomes were the individual components of POCOs and stent thrombosis (ST). Results: POCOs in groups B and C were significantly higher than those in group A. Cardiac death (adjusted hazard ratio [aHR]: 1.957, 95% confidence interval [CI]: 1.126–3.402; p = 0.017) and any repeat revascularization (aHR: 1.597, 95% CI: 1.052–2.424; p = 0.028) rates were significantly higher in group B than in group A. Re-MI (aHR: 1.884, 95% CI: 1.201–2.954; p = 0.006) and death or MI (aHR: 1.438, 95% CI: 1.098–1.884; p = 0.008) were significantly higher in group C than in group B. Conclusions: In this study, prediabetes showed bad clinical outcomes post AMI. However, larger randomized controlled studies including ethnically diverse population are needed to confirm these harmful cardiovascular effects of prediabetes in the future.
AB - Aims: We investigated the 2-year clinical outcomes of patients with acute myocardial infarction (AMI) and prediabetes after new-generation drug-eluting stents implantation. Methods: A total of 11,962 patients with AMI were classified into normoglycemia (group A; 3,080), prediabetes (group B; 3,709), and diabetes (group C; 5,173) groups. The primary outcomes were the patient-oriented composite outcomes (POCOs) defined as all-cause death, recurrent myocardial infarction (Re-MI), and any repeat revascularization. Secondary outcomes were the individual components of POCOs and stent thrombosis (ST). Results: POCOs in groups B and C were significantly higher than those in group A. Cardiac death (adjusted hazard ratio [aHR]: 1.957, 95% confidence interval [CI]: 1.126–3.402; p = 0.017) and any repeat revascularization (aHR: 1.597, 95% CI: 1.052–2.424; p = 0.028) rates were significantly higher in group B than in group A. Re-MI (aHR: 1.884, 95% CI: 1.201–2.954; p = 0.006) and death or MI (aHR: 1.438, 95% CI: 1.098–1.884; p = 0.008) were significantly higher in group C than in group B. Conclusions: In this study, prediabetes showed bad clinical outcomes post AMI. However, larger randomized controlled studies including ethnically diverse population are needed to confirm these harmful cardiovascular effects of prediabetes in the future.
UR - http://www.scopus.com/inward/record.url?scp=85077750437&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077750437&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2019.107994
DO - 10.1016/j.diabres.2019.107994
M3 - Article
C2 - 31881240
AN - SCOPUS:85077750437
VL - 160
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
SN - 0168-8227
M1 - 107994
ER -